Negative correlation between aqueous vascular endothelial growth factor levels and axial length

Japanese Journal of Ophthalmology

Volumn 55, Issue 4, 2011, Pages 401-404

  Sawada, Osamu ^a   Miyake, Taichiro ^a   Kakinoki, Masashi ^a   Sawada, Tomoko ^a   Kawamura, Hajime ^a   Ohji, Masahito ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Aqueous humor; Axial length; Cataract; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGE; AGED; AQUEOUS HUMOR; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE AXIS LENGTH; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; AQUEOUS HUMOR; AXIAL LENGTH, EYE; BIOMETRY; CATARACT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80054772918     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-011-0027-1     Document Type: Article

References (30)

1. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-7 (Pubitemid 24356306)
2. Funatsu H, Yamashita H, Ikeda T, Miura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-6 (Pubitemid 37025424)
3. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256-61
4. Noma H, Funatsu H, Miura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009;116:87-93
5. Sonmez K, Drenser KA, Capone A Jr., Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology. 2008;115:1065-70
6. Nonobe NI, Kachi S, Kondo M, Takai Y, Takemoto K, Nakayama A, et al. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina. 2009;29:579-85
7. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009; Apr 14 (Epub ahead of print)
8. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular agerelated macular degeneration. N Engl J Med. 2004;351:2805-16
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31 (Pubitemid 44511557)
10. Brown DM, Michels M, Kaiser PK, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration. Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65
11. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363-72
12. Spaide RF, Laud K, Fine HF, Klancnik JM Jr., Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-90 (Pubitemid 44197628)
13. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-705
14. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155-8
15. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-8 (Pubitemid 44318179)
16. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina. 2006;26:279-84 (Pubitemid 44318180)
17. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147:298-306
18. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol. 2007;143:601-6
19. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27:419-25 (Pubitemid 46624280)
20. MIu Sultanov, Gadzhiev RV. The characteristics of the course of diabetic retinopathy in myopia. Vestn oftalmol. 1990;106:49-51
21. Moss SE, Klein R, Klein BE. Ocular factors in the incidence and progression of diabetic retinopathy. Ophthalmology. 1994; 101:77-83 (Pubitemid 24044146)
22. Dujić M, Misailović K, Nikolić Lj, Ignjacev M. Occurrence of changes in the eye in diabetic retinopathy with significant myopia. Srp Arh Celok Lek. 1998;126:457-60. (in Serbian)
23. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in the aqueous humor in eyes with myopic choroidal neovascularization. Acta Ophthalmol. 2010; Jan 22 (Epub ahead of print)
24. Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina. 2008;28:1308-13
25. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: One-year results. Am J Ophthalmol. 2009;147:94-100
26. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2009; 147:84-93
27. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. Br J Ophthalmol. 2009;93:150-4
28. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125:1363-6 (Pubitemid 47606601)
29. Lam DS, Leung KS, Mohamed S, Chan WM, Palanivelu MS, Cheung CY, et al. Regional variations in the relationship between macular thickness measurements and myopia. Invest Ophthalmol Vis Sci. 2007;48:376-82 (Pubitemid 47251427)
30. Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol. 1999;155:421-8. (Pubitemid 29370392)